Take our poll: what will be the fates of the stem cell clinic firms sued by the FDA one year from now in October 2019? To be clear, I am asking for your predictions, not what you hope will be the situation a year from now. U.S. Stem Cell, Inc. (USRM) and California Stem Cell […]
Polls on futures of stem cell clinics sued by FDA Read More »
What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can develop an effective stem cell-based therapy for diabetes. You can see a press release on
ViaCyte & CRISPR Therapeutics team up to battle diabetes Read More »
I’m doing a Facebook Live question and answer on stem cells today, Monday, July 23 at Noon USA Pacific Time. Hopefully we’ll cover the exciting, legit research as well as the challenges in the field these days such as for-profit, unproven stem cell clinics out there, as well as everything in between. One possible good
Ask Your Questions on Knoepfler Facebook Live on Stem Cells Today at Noon Read More »
Periodically I also try to post (as I am today) specifically about stem cell good news amongst all the swirling developments out there. You can see the most recent past installment focused on good news here that include vascularized organoids. I recently stumbled on this quote that for me linked up the potential of stem cells
3 bits of stem cell good news Read More »
At the request of the FDA, the DOJ is suing for permanent injunctions against two stem cell clinic firms, U.S. Stem Cell, Inc. and California Stem Cell Treatment Center (and for the latter, its parent chain of around 100 clinics, Cell Surgical Network). What does this big development mean in practical terms and how might it
Helpful Zettler insights from Q&A on FDA suits against stem cell clinics Read More »
The recent news that Texas A&M University has inked a full-blown deal with the direct-to-consumer stem cell clinic firm Celltex struck me as an unusual development. Recently we’ve seen more universities exploring the use of stem cells outside of the traditional FDA clinical trial process that is fundamentally based on an investigational new drug application (IND). Some
Why did Texas A&M ink big deal with stem cell clinic firm Celltex on exosomes? Read More »
2018 has started quickly on the stem cell and regenerative medicine research front with many interesting new papers and a lot of headlines. You can see my predictions for this year here. Below is a list of some of the more notable papers and striking news headlines. Note that just because I listed a news
Reading list of recent stem cell pubs & headlines Read More »
By Anna Everette “In our society, we have an addiction to vertical genetic transmission. It’s called sex and having a child who looks like you”. This was perhaps the most memorable quote from the event’s keynote speaker, Greg Simon, Director of the Biden Cancer Initiative. It also happens to highlight the most compelling reason to
CRISPRcon guest post: Hope for a brighter future Read More »
Is there a proliferating stem cell fake news problem in the biotech world? More broadly, the SEC is cracking down on the mess that is fake biotech news, but what about fake news on stem cell biotechs more specifically? Already in the past year I’ve seen examples of possible stem cell fake news. Hyped press releases (PR)
Stem cell fake news driving biotech investors or vice versa…or what? Read More »
Can science now cure MS in some patients with stem cells or is that near on the horizon? What about stem cells for other serious autoimmune disorders? What are the risks to patients in terms of health, money, and hope? What if patients must find $100,000 or $200,000 just to get into a clinical trial for
Burt Northwestern Stem Cell MS Trial Part 2: Marketing ‘Cure’-Like Outcomes? Read More »